For a patient with newly diagnosed multiple sclerosis who has been on ofatumumab (Kesimpta) for six months, what is the recommended timing for the shingles vaccine and should therapy be paused before or after vaccination?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Shingles Vaccine Timing for MS Patient on Kesimpta

This patient should receive the recombinant zoster vaccine (Shingrix) now without interrupting Kesimpta therapy, as it is a non-live vaccine that can be safely administered during anti-CD20 treatment.

Vaccine Type Selection

The critical first decision is vaccine selection. Only the recombinant zoster vaccine (Shingrix) should be used—never the live-attenuated vaccine (Zostavax) 1. The Kesimpta FDA label explicitly states that live or live-attenuated vaccines should not be given during treatment and until the immune system is no longer weakened 1. Since this patient is already 6 months into therapy, the live vaccine is contraindicated.

Timing Considerations

Current Situation (Already on Therapy)

Since the patient has been on Kesimpta for 6 months, the ideal window for vaccination (before starting therapy) has passed. The FDA label recommends non-live vaccines be given at least 2 weeks before starting Kesimpta "whenever possible" 1. However, this is a preference for optimal immune response, not an absolute requirement.

For patients already on anti-CD20 therapy like ofatumumab, vaccination should proceed without delay:

  • Do not stop Kesimpta for vaccination. The rheumatology guidelines for rituximab (another anti-CD20 antibody) recommend continuing the medication for non-influenza vaccines, though they suggest timing vaccination when the next dose is due and holding the drug for 2 weeks afterward 2. However, this approach is less practical with monthly subcutaneous ofatumumab compared to infused rituximab.

  • Administer Shingrix as a 2-dose series (doses given 2-6 months apart) without interrupting the monthly Kesimpta schedule.

Expected Immune Response

Important caveat: Anti-CD20 therapies substantially reduce antibody responses to vaccines 3. The patient should understand that:

  • Antibody response will likely be blunted or absent
  • However, T-cell responses remain robust even with B-cell depletion 3
  • Some protection is better than none, especially given the increased infection risk with immunosuppression
  • Standard serologic testing may not demonstrate vaccine response, but this does not mean the vaccine provided no benefit

Practical Algorithm

  1. Confirm vaccine type: Shingrix (recombinant) only—verify with pharmacy
  2. Administer first dose now without stopping Kesimpta
  3. Continue monthly Kesimpta as scheduled
  4. Give second Shingrix dose 2-6 months after the first
  5. Monitor for injection site reactions (common with both medications)
  6. Do not attempt serologic testing to confirm response—it will likely be negative but does not reflect true protection

Safety Considerations

The recombinant zoster vaccine has been shown safe in immunosuppressed populations 4. While specific data in MS patients on ofatumumab is limited, the EULAR guidelines note that Shingrix "may replace the live-attenuated vaccine in patients with AIIRD" based on its non-live nature 4. No treatment interruption is needed for safety.

The key pitfall to avoid: Delaying vaccination indefinitely while waiting for an "optimal" time. The patient is already at increased infection risk on immunosuppression, and herpes zoster rates are elevated in MS patients 4. Vaccinate now rather than risk a preventable infection.

Related Questions

In a 30‑year‑old male about to start disease‑modifying therapy for multiple sclerosis, should he receive meningococcal and pneumococcal vaccines (since he has not had them since childhood), are they safe, and how long does the protection last?
I am a 30-year-old male with multiple sclerosis, up to date on childhood vaccines, Tdap, and influenza vaccine, and I plan to start the disease-modifying therapy ofatumumab (Kesimpta). What vaccinations do the CDC or Multiple Sclerosis Society recommend before initiating therapy, and how does ofatumumab affect immune function?
As a 30-year-old with multiple sclerosis who will start disease-modifying therapy, should I receive updated meningococcal (including MenB) and pneumococcal vaccinations despite having received them in childhood, and what other vaccines should I discuss with my primary care physician?
In a healthy 30‑year‑old male with multiple sclerosis, does initiating therapy with Kesimpta (ofatumumab) significantly increase the risk of sepsis, or does it mainly increase the risk of common infections?
With a mild cold/viral upper‑respiratory infection, should I proceed with blood draws for immunoglobulin M, HIV, Epstein‑Barr virus, hepatitis, and JC virus (pre‑multiple sclerosis disease‑modifying therapy work‑up) now, or wait until Monday?
Can we discuss hypertension?
What are omental adhesions?
What is the appropriate management for a diabetic patient with persistent glucosuria and ketonuria, hemoglobin A1c 7.3%, and normal BUN (24 mg/dL) and creatinine (0.85 mg/dL)?
Can dexamethasone and diclofenac be mixed in a single intramuscular injection for treatment of radicular lower back pain?
Should we implement real‑time telemedical oversight (ReTMO) with structured stroke protocols and mobile stroke treatment units (MSTUs) for all suspected acute stroke patients to reduce door‑to‑CT time and improve neurological outcomes?
Should a patient receiving ofatumumab who is varicella‑zoster virus (VZV) antibody positive still be given the recombinant zoster vaccine (Shingrix)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.